Sildenafil Studied in Women With Antidepressant-Associated Sexual Dysfunction

No recurrence or relapse of major depressive disorder occurred in any of

Does Viagra help women?

As determined by the inclusion criteria, the prevalence of sexual problems was high and the mean (SD) number of problems reported was 3.0 (0.7) for the sildenafil group and 2.8 (0.7) the placebo group (P = .21), with 95.8% of women reporting more than 1 complaint. They reported disturbances in desire (87.8%), subjective arousal (80.6%), lubrication (79.6%), orgasm delay (98.7%), and other difficulties (23.6%), which included anorgasmia, lack of pleasure, and pain. Prior to study entry, the women self-reported a mean (SD) of 6.0 (5.2) sexual attempts per month, of which 1.4 (2.0), or 29.6% (34.9%), were considered successful. There were no statistically significant differences between treatment groups in number or type of sexual problems or in number or percentage success of sexual attempts at baseline (Table 1). The difference from baseline to end point in the mean (SD) change in the Clinical Global Impression scale sexual function improvement by intent-to-treat last-observation-carried-forward analyses (ie, lower ordinal score) was 4.8 (0.7) to 2.8 (1.0) with a difference of 1.91 (95% CI, 1.57-2.26) for the sildenafil group vs 4.7 (0.9) to 3.6 (0.9) with a difference of 1.10 (95% CI, 0.75-1.46) for the placebo group, which showed a significant difference of 0.8 (95% CI, 0.6-1.0, P = .001) between groups (Table 2).

Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study

To adjust for potential bias introduced by patients who prematurely discontinued, a more conservative intent-to-treat analysis assigning return-to-baseline values carried forward of those who did not complete the study showed a baseline-to-end point mean difference in the Clinical Global Impression scores of 1.5 (95% CI, 1.1-1.9) among women taking sildenafil vs 0.9 (95% CI, 0.6-1.3) for women taking placebo and a significant 0.6 (95% CI, 0.3-0.8) mean change difference between groups (P = .03). Clinically, 73% of women taking placebo compared with 28% of women taking sildenafil reported no improvement with treatment (Clinical Global Impression score >3 was rated as no improvement). Sexual Function Questionnaires.Table 2 shows the mean (SD) scores on the secondary outcome measures from baseline to study end for both treatment groups. In comparing the baseline sexual function questionnaire domain scores with those at the end of the study, women in the sildenafil group had a higher mean (SD) improvement (orgasm, P=.01) than women taking placebo for all domains except for pain. In the Arizona and the University of New Mexico questionnaires, the ability to reach orgasm and experience orgasm satisfaction was significantly better for those in the sildenafil group than for those in the placebo group for a mean difference from baseline of 0.5 (95% CI, 0.1-1.0; P = .01) for reaching orgasm for the Arizona questionnaire and 0.7 (95% CI, 0.1-1.3; P = .01) for the New Mexico questionnaire. the women continuing a stable dose of antidepressants during the trial (Table 2).

User Name	Reported Effects	Side Effects Experienced	Usage Frequency	Overall Satisfaction
Jenny	Noticed increased sensitivity but mild headaches	Headache, flushes	Weekly	Moderately satisfied
Maria	Felt more aroused, no side effects	None	Occasionally	Satisfied
Lisa	No significant effect	Nausea, dizziness	Rarely	Dissatisfied
Karen	Improved orgasm intensity	Flushing, mild headache	Regular	Satisfied

Mean (SD) baseline values for all endocrine values were within the normal range without significant differences between groups (Table 3).

• Some women report increased genital sensitivity after sildenafil.
• Research suggests possible benefits for women with vascular sexual dysfunction.
• Its use is still controversial and not widely recommended.
• Women should evaluate risks and benefits with their doctor.

Independent of treatment assignment, a comparison of women whose sexual

Product	Dosage	Quantity + Bonus	Price
Kamagra Soft Tabs	100mg	32 Pills	120.11€ 114.39€	Buy
Viagra Generic	200mg	120 + 8 Pills	204.80€ 195.05€	Buy
Viagra Generic	150mg	270 + 10 Pills	326.61€ 311.06€	Buy
Viagra Generic	200mg	360 + 10 Pills	481.98€ 459.03€	Buy
Kamagra	100mg	120 + 6 Pills	330.74€ 314.99€	Buy
Viagra Generic	100mg	60 + 4 Pills	96.36€ 91.77€	Buy
Viagra Generic	25mg	60 + 4 Pills	71.99€ 68.56€	Buy
Viagra Generic	100mg	120 + 6 Pills	149.50€ 142.38€	Buy
Viagra Generic	50mg	270 + 8 Pills	198.48€ 189.03€	Buy
Viagra Generic	25mg	90 + 6 Pills	105.03€ 100.03€	Buy
Kamagra Soft Tabs	100mg	84 + 4 Pills	233.05€ 221.95€	Buy
Viagra Generic	200mg	180 + 10 Pills	277.56€ 264.34€	Buy
Kamagra Soft Tabs	100mg	120 + 6 Pills	311.78€ 296.93€	Buy
Kamagra	100mg	180 + 6 Pills	436.79€ 415.99€	Buy
Viagra Generic	50mg	60 + 4 Pills	83.93€ 79.93€	Buy

function improved with those whose sexual function did not improve showed

What Are the Side Effects in Women?

In measuring depression, at baseline, women in both groups had nearly identical Hamilton scores. At the end of the study, their scores remained similar (P=.90) indicating persisting remission in depression. The difference in change scores between treatment groups did not achieve statistical significance (P = .86). Among women who received treatment according to protocol, 3 women in the placebo group and 1 in the sildenafil group developed intermittent Hamilton depression scores of between 10 and 15. These were self-limited, transient, symptomatic changes distinguished from major depressive disorder relapse and not considered clinically meaningful to warrant intervention. higher mean baseline levels of free testosterone (P ≤ .01) and thyroxine (P ≤ .01) among SRI-associated sexual dysfunction treatment responders.

• Sildenafil's effect duration in women may range from 4 to 6 hours.
• It may help women experiencing low libido linked to blood flow issues.
• The drug’s efficacy in women is less predictable than in men.
• Female sexual dysfunction has multiple causes beyond blood flow.

At study end, 76.9% (30 of 39) of women took a mean (SD) dose of 91.7 (19.8) mg of sildenafil and 86.5% (32 of 37) took 93.1 (17.5) mg of placebo.

References (17)

Adjusted means (SDs) were determined and reported. Where applicable, 95% confidence intervals (CIs) are provided. Analyses were performed with SAS version 9.1.3 (SAS Institute Inc, Cary, North Carolina). One hundred women (Figure) of the 145 screened met eligibility requirements. Among the most frequent causes for exclusion were ineligible protocol criteria (ie, lack of acceptable and verifiable form of contraception, perimenopausal with irregular cycles or amenorrhea, non-SRI sexual dysfunction augmentation, switching antidepressant agent, other treatments for sexual dysfunction), and other miscellaneous reasons (partner issues, abnormal Papanicolaou test results, medical comorbidity, excessive alcohol use, or relationship or partner problems).

Exclusion Criteria

Two eligible participants were withdrawn after they sildenafil generic were screened but before they were randomized. One patient had a change in antidepressant dose made by her primary care physician. The other patient withdrew due to her partner's serious injuries. The 2 nonrandomized and untreated women did not differ on any demographic characteristics from those who entered the trial and were not included in the analyses. A total of 98 women were randomly assigned to receive active sildenafil (n = 49) or placebo (n = 49). The maximum dose for the study was 100 mg.

25 Answers Page 2

Serum blood samples drawn at baseline and at study end, before 11 AM on days 1 to 10 of the menstrual period (follicular phase), were stored at −80°C until assayed and measured following prescribed procedures (eg, chemiluminescent enzyme immunoassay, microparticle enzyme immunoassay, radioimmunoassay) at the Reproductive Endocrine Reference Laboratory at Massachusetts General Hospital, Boston. Full analysis procedures with lower limits of detection reported for assays performed at the Massachusetts General Hospital General Clinical Research Center core laboratory using commercially available kits are published by the manufacturer and available on request. Baseline demographics, safety, and tolerability evaluations were compared using descriptive statistics by χ2 and Fisher exact tests (when cell sizes were <5). Independent samples t tests compared baseline patient characteristics and Clinical Global Impression sexual function scores between the study groups at end point. The χ2 analyses were used to evaluate group differences in categorical measures.

Corresponding author

Analyses were based on intent-to-treat with the last-observation-carried-forward analyses performed on all variables and included data from all protocol-treated patients. All randomized patients received and took at least 1 dose of study trial medication, had at least 1 efficacy assessment, and were included regardless of protocol deviations or whether they completed the study. The final analysis included women who completed the trial, but for the women who did not complete the trial, their baseline value was carried forward in separate analyses. The change in sexual functioning by Clinical Global Impression sexual function score and all other questionnaires from baseline to each patient's own end point were the dependent measures of efficacy. A repeated measures analysis of variance was used to determine differences between placebo and sildenafil in the change from baseline to end point for the measures of efficacy and depression severity (time × group interaction). The mean (SD) number of doses per 2-week interval was 5.0 (2.5) mg for sildenafil and 5.2 (2.5) for placebo, which

Similar questions

In addition, exact nonparametric methods were applied to the efficacy measures to substantiate results that rely on distributional assumptions. Findings were also confirmed with analysis of covariance and Wilcoxon rank sum tests for primary analyses. All statistical tests were 2-sided, and all hypotheses were evaluated at the 5% significance level. The F test of the overall hypothesis test was first conducted before multiple comparisons analyses. Sample-size calculations were based on detecting a difference in full response rates at 8 weeks, assuming a response rate of 70% for sildenafil and 35% for placebo.

How much time does it take for Viagra to work for females?

Thus, a sample size of 82 evaluable patients (41 per group) was expected to detect a significant difference with 90% power for a type I error rate of α = .05 between sildenafil and placebo (2-sided). Assuming 20% attrition, 100 patients were planned to be randomized and 98 patients were entered. The sample size determination assumed no interactions of treatment with site or antidepressant. The primary analysis was according to assignment at randomization. In addition to determination of this narrow measure of efficacy based on all randomized patients and imputing the worst rank scores for early exclusions due to protocol violations before and without taking the trial drug, there was a general efficacy analysis for all protocol-treated patients and all trial completers. supports the notion that the lack of efficacy in placebo patients was not due to a lack of attempts (P = .67).

Serious side effects (seek immediate help)

The mean (SD) age of the women was 36.7 (7.1) years. They had been taking antidepressant medication for 27.7 (34.6) months. Distribution of prescribed antidepressants was comparable between groups. There were no statistically significant differences between baseline demographics in the assigned treatment groups (Table 1). Systematic review for any protocol deviations in patient enrollment was undertaken before unbinding.

Exploratory Phase 2b RESPOND Study, Completed in 2023

The 98 randomized women constituted the last-observation-carried-forward analysis. Seventy-six women (77.6%) completed the study: with 75.5% (37 of 49) in the placebo group and 79.6% (39 of 49) in the sildenafil group and constituted the completer population. Nine women in the placebo group and 4 in the sildenafil group discontinued prematurely for lack of efficacy. The other 6 in sildenafil and 3 in the placebo groups were lost to follow-up. No discontinuations for intolerable or serious adverse events were reported (Figure).